U.S. markets close in 2 hours 44 minutes
  • S&P 500

    3,571.30
    +13.76 (+0.39%)
     
  • Dow 30

    29,498.52
    +235.04 (+0.80%)
     
  • Nasdaq

    11,876.20
    +21.23 (+0.18%)
     
  • Russell 2000

    1,815.94
    +30.60 (+1.71%)
     
  • Crude Oil

    42.99
    +0.57 (+1.34%)
     
  • Gold

    1,838.00
    -34.40 (-1.84%)
     
  • Silver

    23.62
    -0.74 (-3.05%)
     
  • EUR/USD

    1.1846
    -0.0017 (-0.14%)
     
  • 10-Yr Bond

    0.8500
    +0.0210 (+2.53%)
     
  • GBP/USD

    1.3311
    +0.0019 (+0.15%)
     
  • USD/JPY

    104.3300
    +0.5020 (+0.48%)
     
  • BTC-USD

    18,300.87
    -153.88 (-0.83%)
     
  • CMC Crypto 200

    362.01
    +0.58 (+0.16%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    25,527.37
    -106.93 (-0.42%)
     

Recap: ShockWave Medical Q3 Earnings

Benzinga Insights
·1 min read

Shares of ShockWave Medical (NASDAQ:SWAV) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 17.39% year over year to ($0.38), which beat the estimate of ($0.55).

Revenue of $19,590,000 higher by 72.86% from the same period last year, which beat the estimate of $14,690,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

ShockWave Medical hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Nov 09, 2020

View more earnings on SWAV

Time: 04:30 PM

ET Webcast URL: https://ir.shockwavemedical.com/events/event-details/shockwave-medical-inc-q3-2020-earnings-conference-call

Recent Stock Performance

Company's 52-week high was at $79.74

52-week low: $22.01

Price action over last quarter: Up 56.79%

Company Profile

ShockWave Medical Inc a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Its intravascular lithotripsy technology is used in the treatment of calcified plaque. Geographically, the company generates its revenue from the United States.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.